Ahamed Lazim Vattoth

Mr. Ahamed Lazim Vattoth

Weill Cornell Medical College in Qatar, Doha, Ad Dawḩah, Qatar

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MAMuna Almasri
Muna Almasri
KBKhalifa Bshesh
Khalifa Bshesh
WKWafa Khan
Wafa Khan
MMMalik Mushannen
Malik Mushannen
MSMohammad A. Salameh
Mohammad A. Salameh
DZDalia Zakaria
Dalia Zakaria
Few guidelines exist for COVID-19 vaccination amongst cancer patients, fostering uncertainty regarding the immunogenicity, safety, and effects of cancer therapies on vaccination, which this review aims to address. A literature review was conducted to include the latest articles covering the immunogenicity and safety of COVID-19 vaccination in patients with solid and hematologic cancers receiving various treatments. Lower seropositivity following vaccination was associated with malignancy (compared to the general population), and hematologic malignancy (compared to solid cancers). Patients receiving active cancer therapy (unspecified), chemotherapy, radiotherapy, and immunosuppressants generally demonstrated lower seropositivity compared to healthy controls; though checkpoint inhibition, endocrine therapy, and cyclin dependent kinase inhibition did not appear to affect seropositivity. Vaccination appeared safe and well-tolerated in patients with current or past cancer and those undergoing treatment. Adverse events were comparable to the general population, but inflammatory lymphadenopathy following vaccination was commonly reported and may be mistaken for malignant etiology. Additionally, radiation recall phenomenon was sporadically reported in patients who had received radiotherapy. Overall, while seropositivity rates were decreased, cancer patients showed capacity to generate safe and effective immune responses to COVID-19 vaccination, thus vaccination should be encouraged and hesitancy should be addressed in this population.

1 October 2025 in Journal Of Clinical Neurophysiology
Verified
Journal Article
Open access
ANAreej Nauman
Areej Nauman
AVAhamed Lazim Vattoth
Ahamed Lazim Vattoth
GMGayane Melikyan
Gayane Melikyan
MAMusab Ali
Musab Ali
YOYaser Othman
Yaser Othman
NHNaim Haddad
Naim Haddad
Purpose: In patients with epilepsy who achieve seizure freedom, physicians may consider discontinuing antiseizure medications, often using EEG beforehand to guide the decision. This study evaluates the gain in detection of epileptiform discharges (EDs) in 24-hour video EEG (VEEG) monitoring in seizure-free patients. Methods: The authors identified patients with epilepsy who were seizure free on antiseizure medications and had undergone 24-hour VEEG after an unrevealing routine EEG. The authors evaluated the yield and latency of observed EDs in the VEEG study. The authors compared the rate of ED detection during the first 60 minutes versus later in the recording. Results: Of the 27 patients, aged 19 to 51 years, 10 (37%) exhibited EDs on 24-hour VEEG. The latency to the first EDs ranged from 52 to 748 minutes, with a median of 164 minutes. Nine of these 10 patients (90%) had their EDs appear only after the first 60 minutes of recording. In other words, prolonging the EEG beyond 1 hour yielded an additional 33.3% of patients with EDs that a 1-hour recording would have missed. Younger age and presence of EDs on a past EEG were predictive of the presence of EDs on VEEG ( P = 0.040 and P = 0.039 respectively). Conclusions: The results suggest that 24-hour VEEG is more sensitive in detecting EDs than routine EEG in seizure-free patients and thus may be superior in individualized risk assessments for seizure recurrence on potential antiseizure medication discontinuation.